Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Isofol Medical AB ( (SE:ISOFOL) ) just unveiled an announcement.
Isofol Medical AB announced its participation in the ESMO cancer congress in Berlin, where it will present an abstract on its ongoing phase Ib/II study of arfolitixorin. This study, conducted in collaboration with Charité – Universitätsmedizin Berlin, explores a new dosage regimen for arfolitixorin in combination with standard chemotherapy for metastatic colorectal cancer. The participation in ESMO is expected to enhance Isofol’s visibility and strengthen its scientific network, as the company aims to address the urgent need for improved colorectal cancer treatments.
More about Isofol Medical AB
Isofol Medical AB is a biotechnology company focused on enhancing the quality of life and prognosis for patients with severe cancer forms. The company is developing arfolitixorin, a clinical-stage drug candidate aimed at improving the efficacy of first-line treatments for solid tumors, particularly in colorectal cancer, which is the third most common cancer globally. Isofol Medical AB is listed on Nasdaq Stockholm.
Average Trading Volume: 1,065,779
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK210.7M
See more insights into ISOFOL stock on TipRanks’ Stock Analysis page.